Calcium Channel Blockers (CCBs) - USMLE Step 1 High-Yield Guide

QUICK ORIENTATION: Three Chemical Classes

MECHANISM OF ACTION

• Vascular smooth muscle: Calcium influx drives contraction. Block it → arteriolar vasodilation → decreased SVR (afterload reduction). CCBs dilate arterioles, NOT veins.
• Cardiac muscle: Calcium drives both contractility (inotropy) and the slow depolarization of SA/AV nodal tissue (chronotropy/dromotropy).

Lippincott Illustrated Reviews: Pharmacology - Note: Diltiazem is the strongest coronary vasodilator, nifedipine has the most adverse effects (18%), and verapamil has the most AV conduction slowing.

DRUG-BY-DRUG HIGH-YIELD BREAKDOWN

1. Nifedipine / Amlodipine (DHPs)

• Potent arteriolar vasodilation → decreased SVR
• Minimal cardiac conduction effect (no chronotropy/dromotropy)
• Reflex tachycardia with short-acting nifedipine (baroreceptor response to rapid BP drop)
• Amlodipine has an extremely long half-life (30-50 hours) - no sustained-release formulation needed

• Hypertension (first-line in Black patients, diabetics, asthmatics, peripheral vascular disease)
• Stable and vasospastic (Prinzmetal) angina
• Nimodipine: subarachnoid hemorrhage (crosses BBB, prevents cerebral vasospasm)
• Nicardipine/Clevidipine: IV use for hypertensive urgency/emergency

• Peripheral edema (capillary dilation, not heart failure)
• Reflex tachycardia (especially short-acting nifedipine)
• Gingival hyperplasia (nifedipine - classic USMLE finding)
• Headache, flushing, dizziness

2. Verapamil (Phenylalkylamine)

• Most negative inotropic CCB
• Negative chronotropy (slows HR), negative dromotropy (slows AV conduction)
• Weaker vasodilator than DHPs

• Hypertension
• Angina (stable, vasospastic)
• Rate control in atrial fibrillation/flutter and SVT (especially AVNRT)
• Migraine and cluster headache prophylaxis
• Hypertrophic obstructive cardiomyopathy (HOCM) - when beta-blockers fail

• Constipation (most common SE - classic USMLE answer)
• First-degree AV block (dose-dependent)
• Hypotension
• Bradycardia

• AV block (2nd or 3rd degree)
• Sick sinus syndrome (without pacemaker)
• HFrEF (worsens due to negative inotropy)
• WPW + atrial fibrillation - NEVER use verapamil (blocks AV node, forces conduction through accessory pathway → VF)
• Concurrent beta-blocker use IV (severe bradycardia/AV block)

3. Diltiazem (Benzothiazepine)

• Intermediate between verapamil and nifedipine
• Affects both cardiac and vascular smooth muscle
• Less negative inotropy than verapamil
• Best side-effect profile among CCBs (only 2% adverse effect frequency)

• Same as verapamil for rate control in AFib/flutter, SVT
• Angina (excellent for vasospastic angina - coronary vasodilator)
• Hypertension

• Bradycardia, AV block (less than verapamil)
• Hypotension

CLINICAL INDICATIONS MATRIX

ADVERSE EFFECT SUMMARY TABLE

USMLE TRAPS - HIGH YIELD

• Lippincott Illustrated Reviews: Pharmacology

• Katzung's Basic and Clinical Pharmacology, 16th Ed.

RANKING COMPARISONS (Tested Directly on NBME)

PHARMACOKINETICS TO REMEMBER

HIGH-YIELD CLINICAL PEARL: CCB vs Beta-Blocker Comparison

TAKE-HOME POINTS (USMLE Speed Review)

1. "pines" = DHPs = vascular selective = no rate slowing = peripheral edema + reflex tachycardia + gingival hyperplasia
2. Verapamil = strongest cardiac effect = constipation = best for SVT/AFib rate control; AVOID in HFrEF, AV block, WPW+AFib
3. Diltiazem = intermediate; best side-effect profile (2%); great for vasospastic angina
4. Nimodipine = SAH only (cerebral vasospasm prevention)
5. Non-DHPs CONTRAINDICATED in HFrEF - only amlodipine is safe in HF
6. Short-acting nifedipine contraindicated post-MI - reflex tachycardia increases cardiac demand
7. CCB OD = hyperglycemia + bradycardia/hypotension; treat with high-dose insulin + calcium
8. WPW + AFib + Verapamil = VFib - most dangerous CCB drug-condition combination
9. CCBs preferred over beta-blockers in: asthma, DM, PVD, Black patients (for HTN)
10. Amlodipine half-life = 30-50h - slowest onset and longest duration

• Mechanism & Physiology (what you need to know cold)
• Drug-by-drug or concept-by-concept breakdown (NBME loves specifics)
• Clinical Indications Matrix (when to use / when to avoid)
• Adverse Effects Table
• USMLE TRAPS (the exact wrong answers NBME plants)
• Ranking Comparisons (directly tested)
• Take-Home Points (speed review bullets)

HYDRALAZINE - USMLE Step 1 | NBME-Style Guide

MECHANISM & PHYSIOLOGY

1. Reduces intracellular calcium in arteriolar smooth muscle → vasodilation
2. Inhibits oxidases → prevents breakdown of endogenous nitric oxide (NO) → enhances NO signaling → additional vasodilation
3. Acts on arterioles only - NOT veins (critical USMLE distinction)

• Decreased SVR (afterload ↓)
• Increased cardiac output (compensatory)
• Reflex tachycardia (baroreceptor response to BP drop)
• NO effect on preload (veins are spared)

PHARMACOKINETICS (TESTED HEAVILY)

The Acetylator Phenotype - HIGH YIELD

THERAPEUTIC USES

1. Hypertension (3rd or 4th line)

• Not a first-line agent due to reflex tachycardia and tachyphylaxis
• Used when first- and second-line agents are insufficient
• Must always be used with a beta-blocker (to blunt reflex tachycardia) and a diuretic (to prevent edema)

2. Heart Failure with Reduced EF (HFrEF) - HIGHEST YIELD USE

• Hydralazine + Isosorbide dinitrate (BiDil) = the fixed-dose combination
• Specifically shown to improve survival in self-identified African American patients with HFrEF who are already on guideline-directed therapy (beta-blocker + ACEi or ARB) - from the A-HeFT trial
• Rationale: Black patients tend to have lower NO bioavailability and less RAAS activation - hydralazine/nitrate combo restores NO signaling
• Also used when patients are intolerant of ACEi/ARBs (e.g., bilateral renal artery stenosis, angioedema from ACEi, pregnancy)

3. Hypertensive Emergencies in Pregnancy (Eclampsia/Pre-eclampsia)

• IV hydralazine is a classic first-line agent for severe hypertension in pregnancy
• Safe for fetus; does not affect uteroplacental blood flow significantly
• Given alongside magnesium sulfate (for seizure prophylaxis in eclampsia)

ADVERSE EFFECTS TABLE

DRUG-INDUCED LUPUS (DIL) - DEDICATED SECTION

• Sulfasalazine
• Hydralazine ← most classic
• Isoniazid (INH)
• Procainamide ← most common cause overall
• Penicillamine

CLINICAL INDICATIONS & CONTRAINDICATIONS

COMPARISON: HYDRALAZINE vs. MINOXIDIL

USMLE TRAPS

RANKINGS & COMPARISONS

TAKE-HOME POINTS

1. Mechanism: Direct arteriolar vasodilator (NOT venous) → decreases afterload, increases CO, triggers reflex tachycardia
2. Must combine with beta-blocker (anti-tachycardia) + diuretic (anti-edema) when used for HTN
3. HFrEF use: Hydralazine + isosorbide dinitrate = proven survival benefit in Black patients (A-HeFT trial) and as alternative when ACEi/ARB is not tolerated
4. Pregnancy: IV hydralazine = first-line for hypertensive emergency in eclampsia (with MgSO4 for seizures)
5. Drug-induced lupus: ANA+, anti-histone+, anti-dsDNA negative, no renal involvement, reverses on stopping drug
6. Slow acetylators = higher drug levels = more DIL risk
7. Peripheral neuropathy = B6 deficiency (same as INH) → treat with pyridoxine
8. Dose >200 mg/day = 10-20% incidence of lupus syndrome
9. Hydralazine vs Minoxidil: both arteriolar dilators, but minoxidil opens K+ channels, is more potent, and causes hypertrichosis
10. Never give alone in CAD - reflex tachycardia increases ischemia risk

HYPERTENSIVE EMERGENCY - USMLE Step 1 | NBME-Style Guide

DEFINITIONS - THE FIRST THING TESTED

PHYSIOLOGY: WHY THE ORGANS GET DAMAGED

• Brain: Loss of autoregulation → forced hyperperfusion → vasogenic cerebral edema → hypertensive encephalopathy; or alternatively, thrombotic/hemorrhagic stroke
• Heart: Increased afterload → LV strain → acute decompensated heart failure, pulmonary edema; or plaque rupture → ACS
• Kidney: Fibrinoid necrosis of renal afferent arterioles → microangiopathic hemolytic anemia (MAHA) + acute kidney injury
• Aorta: Shear stress on aortic wall → dissection
• Eye: Retinal arteriolar damage → flame hemorrhages, papilledema, cotton-wool spots

TARGET ORGAN DAMAGE - INCIDENCE TABLE (HIGH YIELD)

TREATMENT FRAMEWORK - THE GOLDEN RULE

Reduce mean arterial pressure (MAP) by no more than 25% within the first hour.

• Exception - Aortic dissection: Target SBP <120 mmHg within minutes (fastest reduction needed)
• Exception - Ischemic stroke (no tPA): Do NOT aggressively lower BP - relative hypertension maintains penumbra perfusion; only treat if SBP >220 or DBP >120
• Exception - Ischemic stroke (+ tPA given): Keep SBP <180 mmHg to prevent hemorrhagic transformation

DRUG SELECTION BY CLINICAL SCENARIO

1. Aortic Dissection

• Why: Must reduce both BP AND heart rate (HR)/force of contraction simultaneously - decreased dP/dt (rate of pressure rise) is the goal
• Critical rule: Give beta-blocker BEFORE vasodilator - a pure vasodilator causes reflex tachycardia → increases shear stress → worsens dissection
• Target: SBP <120 mmHg as fast as safely possible

2. Hypertensive Encephalopathy

• Gradual MAP reduction of 25% in first hour
• Avoid nitroprusside (can increase ICP via cerebral vasodilation)

3. Acute Ischemic Stroke

• If tPA given: Keep SBP <180/DBP <105
• If no tPA: Only treat if BP >220/120; otherwise permissive hypertension

4. Intracerebral Hemorrhage (ICH)

• Target SBP <140 within first hour (to limit hematoma expansion)

5. Acute HF + Pulmonary Edema

• Nitrates primarily reduce preload (venodilation) → decongest lungs fast
• Avoid beta-blockers (negative inotropes in acute decompensation)

6. Acute Coronary Syndrome (ACS)

• Reduces preload/afterload, relieves coronary spasm
• Avoid direct vasodilators (reflex tachycardia increases O2 demand)

7. Pheochromocytoma Crisis / MAOI + Tyramine / Cocaine

• Pure catecholamine excess state → alpha-receptor blockade is critical
• NEVER give beta-blocker first (unopposed alpha activity → paradoxical severe HTN)
• For cocaine: benzodiazepines + phentolamine; avoid beta-blockers

8. Eclampsia / Severe Preeclampsia

• Add Magnesium sulfate for seizure prophylaxis (NOT an antihypertensive)
• Avoid: ACEi, ARBs, nitroprusside (all teratogenic/fetal harm)

9. Hypertensive Emergency with Renal Impairment

• Uniquely increases renal blood flow, diuresis, and natriuresis while lowering BP
• Renoprotective - preferred when renal perfusion is a concern

10. Perioperative / Post-op Hypertension

• Clevidipine: onset <2 min, half-life <1 min; ideal for OR/ICU titration

DRUG PROFILES - IV AGENTS

Sodium Nitroprusside

• Class: Balanced arterial + venous vasodilator (NO donor)
• Mechanism: Spontaneously releases NO → activates sGC → ↑cGMP → smooth muscle relaxation (both arteries and veins)
• Onset: Seconds; Duration: 1-2 min (easiest to titrate)
• Use: Severe HTN emergencies (most conditions except pheochromocytoma); aortic dissection (with beta-blocker)
• Major SE: Cyanide toxicity (high dose >5 mcg/kg/min, prolonged use, renal failure); thiocyanate toxicity
  • Mechanism: Nitroprusside → releases CN⁻ → metabolized by rhodanese (needs thiosulfate) → thiocyanate (renally excreted)
  • Treat cyanide toxicity with: sodium thiosulfate (provides sulfur donor) or hydroxocobalamin
• Other SEs: Rebound hypertension on discontinuation, raised ICP, methemoglobinemia

IV Labetalol

• Class: Combined alpha-1 and beta (nonselective) blocker (ratio alpha:beta = 1:7)
• Mechanism: Blocks both alpha-1 (vasodilation) and beta (decreased CO, HR)
• Onset: 5-10 min; Duration: 3-6 hours
• Best for: Aortic dissection, stroke, eclampsia, most general HTN emergencies
• Avoid in: Acute decompensated HF, asthma/COPD (beta-blockade), high-degree AV block
• Advantage: Lowers BP WITHOUT reflex tachycardia (because of beta-blockade)

IV Nicardipine

• Class: Dihydropyridine CCB (IV form)
• Mechanism: Arteriolar vasodilation (no cardiac conduction effect)
• Onset: 5-15 min; Duration: 4-6 hours
• Best for: Stroke (ischemic or hemorrhagic), post-op HTN, eclampsia, general HTN emergency
• SE: Reflex tachycardia, headache, flushing

Clevidipine

• Class: Ultrashort DHP CCB (IV only)
• Half-life: <1 minute (metabolized by blood esterases)
• Best for: Perioperative/OR/ICU use where precise, rapid BP titration needed
• SE: Reflex tachycardia; lipid emulsion vehicle (caution in hypertriglyceridemia)

IV Nitroglycerin

• Class: Nitrate (primarily venodilator)
• Mechanism: Converts to NO → venodilation >> arterial dilation → decreased preload primarily
• Best for: ACS, acute decompensated HF with pulmonary edema
• SE: Headache, tachycardia, methemoglobinemia (rare), tolerance with prolonged use

Phentolamine

• Class: Non-selective alpha-blocker (competitive)
• Best for: Pheochromocytoma crisis, MAOI + tyramine reaction, cocaine-induced HTN emergency
• SE: Reflex tachycardia (no beta-blockade), hypotension

Fenoldopam

• Class: Selective dopamine D1 receptor agonist
• Mechanism: Vasodilation via D1 activation; also increases renal perfusion + natriuresis
• Best for: HTN emergency with renal impairment (preferred over nitroprusside in renal failure)
• Advantage over nitroprusside: No cyanide toxicity risk; increases (not decreases) renal blood flow
• SE: Tachycardia, hypokalemia, elevated intraocular pressure (avoid in glaucoma)

Esmolol

• Class: Ultra-short acting, cardioselective beta-1 blocker (IV)
• Half-life: ~9 minutes
• Best for: Aortic dissection (with nitroprusside), perioperative tachycardia + HTN
• Avoid: Asthma, acute decompensated HF

DRUG SELECTION MATRIX (NBME SPEED REFERENCE)

USMLE TRAPS

TAKE-HOME POINTS

1. Emergency = TOD present; Urgency = no TOD - numbers alone don't define emergency
2. Max 25% MAP reduction in first hour - faster reduction causes ischemia in adapted vasculature
3. Aortic dissection: Beta-blocker FIRST (labetalol/esmolol), THEN nitroprusside if needed; target SBP <120 fast
4. Stroke (no tPA): Permissive HTN - only treat if SBP >220; do not rush
5. Stroke + tPA: Keep SBP <180 to prevent hemorrhagic conversion
6. ACS / Pulmonary edema: IV nitroglycerin (preload reduction)
7. Pheo/cocaine/MAOI: Phentolamine FIRST - never beta-blocker first (unopposed alpha = disaster)
8. Eclampsia: Hydralazine/labetalol + MgSO4 (for seizures); avoid ACEi/ARBs
9. Renal failure: Fenoldopam > Nitroprusside (fenoldopam increases renal flow; nitroprusside accumulates thiocyanate)
10. Nitroprusside toxicity: Cyanide → lactic acidosis → treat with sodium thiosulfate or hydroxocobalamin

RANOLAZINE - USMLE Step 1 | NBME-Style Guide

MECHANISM & PHYSIOLOGY - THE CORE CONCEPT

Step-by-step mechanism:

1. Blocks the late inward sodium current (late I-Na) - the primary antianginal mechanism
   • During ischemia, the late Na⁺ current becomes abnormally prolonged and increased
   • This excess Na⁺ entry activates the Na⁺/Ca²⁺ exchanger (NCX), which then imports Ca²⁺ into the cell
   • The resulting calcium overload → increases diastolic tension → reduces coronary perfusion → worsens ischemia
2. Blocking late I-Na → less Na⁺ enters → NCX imports less Ca²⁺ → decreased intracellular Ca²⁺ → decreased diastolic wall tension → improved myocardial relaxation and coronary perfusion
3. Net effect: Reduced myocardial oxygen consumption and improved perfusion WITHOUT altering heart rate or blood pressure

Also blocks:

• IKr (rapid delayed rectifier K⁺ current) - at therapeutic doses, this prolongs QT slightly
• At higher concentrations: early I-Na (like class I antiarrhythmic), mild IKr and ICa blockade

The key distinction:

Ranolazine does NOT reduce HR, does NOT lower BP, does NOT reduce contractility meaningfully. It works purely through metabolic/ionic channel modulation.

COMPARISON OF ANTIANGINAL MECHANISMS

THERAPEUTIC USES

1. Chronic Stable Angina (FDA-Approved Indication)

• Used when first-line agents (beta-blockers, nitrates, CCBs) are insufficient or not tolerated
• Add-on therapy to any combination of: beta-blockers, nitrates, CCBs
• Increases exercise duration, delays onset of anginal symptoms, and delays ST depression on treadmill testing
• Reduces frequency of anginal episodes and sublingual nitroglycerin use

2. Refractory Angina (Most High-Yield Use)

• "A patient with stable angina is already on a maximized beta-blocker and long-acting nitrate but continues to have angina. HR is 52, BP is 108/70. What do you add?" → Ranolazine
• Perfect when you cannot add more HR-lowering or BP-lowering drugs

3. Antiarrhythmic Use (Off-Label, Not FDA-Approved as Antiarrhythmic)

• Shown to reduce AF, SVT, and ventricular arrhythmias in CAD trials
• Shortens action potential duration in long QT syndrome type 3 (LQT3) specifically - because LQT3 is caused by excessive late I-Na (gain-of-function SCN5A mutation), which ranolazine directly blocks
• Under investigation in combination with dronedarone for AF suppression
• NOT FDA-approved as an antiarrhythmic - this is a classic USMLE trap

PHARMACOKINETICS

ADVERSE EFFECTS

DRUG INTERACTIONS - CRITICAL FOR USMLE

Hepatic cirrhosis → CONTRAINDICATED

• Severe hepatic impairment markedly increases QT prolongation risk

CLINICAL INDICATIONS & CONTRAINDICATIONS

USMLE TRAPS

• Strong CYP3A inhibitors (ketoconazole, ritonavir, clarithromycin) = Contraindicated entirely
• Moderate CYP3A inhibitors (diltiazem, verapamil, grapefruit juice) = Reduce dose to 500 mg BID (do not stop)
• NBME will present a patient on ranolazine who starts diltiazem or verapamil for rate control - the correct answer is to reduce the ranolazine dose, NOT stop it.

RANKINGS & COMPARISONS

TAKE-HOME POINTS

1. Mechanism: Blocks late I-Na → prevents Ca²⁺ overload via NCX → reduces diastolic tension and O2 demand
2. No hemodynamic effects - HR unchanged, BP unchanged, contractility unchanged
3. Use: Chronic stable angina as add-on or when beta-blockers/CCBs cannot be used/maximized
4. NOT for acute attacks - sublingual NTG is for acute; ranolazine is prophylactic
5. Metabolized by CYP3A - contraindicated with strong CYP3A inhibitors/inducers; dose-limit with moderate inhibitors (diltiazem, verapamil, grapefruit)
6. QTc prolongs (blocks IKr) BUT no torsades - because late I-Na block suppresses EADs
7. LQT3 - ranolazine shortens QT (because LQT3 = excess late I-Na)
8. NOT FDA-approved as antiarrhythmic despite antiarrhythmic properties
9. Mild creatinine elevation = pharmacologic artifact, not true AKI
10. Contraindicated in hepatic cirrhosis (severe QTc prolongation risk) and with strong CYP3A inhibitors